Compassionate Use of Lumacaftor/Ivacaftor in Cystic Fibrosis: Spanish Experience-Reference-Cited by-同舟云学术

Compassionate Use of Lumacaftor/Ivacaftor in Cystic Fibrosis: Spanish Experience

Published:2018-12 Issue:12 Volume:54 Page:614-618
ISSN:0300-2896
Container-title:Archivos de Bronconeumología
language:en
Short-container-title:Archivos de Bronconeumología

Author:

Diab-Cáceres Layla,Girón-Moreno Rosa María,Pastor-Sanz María Teresa,Quintana-Gallego Esther,Delgado-Pecellín Isabel,Blanco-Aparicio Marina,Maiz Luis,García-Clemente Marta María,Luna-Paredes Carmen,Mondéjar-López Pedro,Ruiz-de-Valbuena Marta,Fernández Ofelia,Barrio Maribel,González Maribel,López-Neyra Alejandro,Cols-i-Roig María,Palou-Rotger Alexandre,Gómez-de-Terreros-Caro Francisco Javier

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference8 articles.

1. Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis;Elborn;Lancet Respir Med,2016

2. Lumacaftor–ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR;Wainwright;N Engl J Med,2015

3. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study;Konstan;Lancet Respir Med,2017

4. Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease;Hubert;J Cyst Fibros,2017

5. Management of pulmonary exacerbations in cystic fibrosis: still an unmet medical need in clinical practice;Justicia;Expert Rev Respir Med,2015

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of SARS-CoV-2 infection in patients with cystic fibrosis undergoing CFTR channel modulators treatment: a literature review;Respiratory Research;2023-11-13

2. Brazilian guidelines for the pharmacological treatment of the pulmonary symptoms of cystic fibrosis. Official document of the Sociedade Brasileira de Pneumologia e Tisiologia (SBPT, Brazilian Thoracic Association);Jornal Brasileiro de Pneumologia;2023-05-02

3. Ventilatory Threshold and Risk of Pulmonary Exacerbations in Cystic Fibrosis;Respiratory Care;2023-04-04

4. Real life evaluation of the multi-organ effects of Lumacaftor/Ivacaftor on F508del homozygous cystic fibrosis patients;BMC Pharmacology and Toxicology;2022-10-20

5. Cystic fibrosis: candidate selection and impact of the cystic fibrosis transmembrane conductance regulator therapy;Current Opinion in Organ Transplantation;2022-06